Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198. On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Keohane C, Radia DH, Harrison CN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/884bd7fa1e2b4de29133247f5cacc29b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:884bd7fa1e2b4de29133247f5cacc29b
record_format	dspace
spelling	oai:doaj.org-article:884bd7fa1e2b4de29133247f5cacc29b2021-12-02T05:03:30ZTreatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]1177-54751177-5491https://doaj.org/article/884bd7fa1e2b4de29133247f5cacc29b2013-10-01T00:00:00Zhttp://www.dovepress.com/corrigendum-treatment-and-management-of-myelofibrosis-in-the-era--a14840https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198. On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)." should have been "Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)." On page 193 in the same paragraph note that "Post-Essential Thrombocythemia Myelofibrosis: PERSIST)." should have been "Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1)."Read the original articleKeohane CRadia DHHarrison CNDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 231-232 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Keohane C Radia DH Harrison CN Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
description	Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198. On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)." should have been "Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)." On page 193 in the same paragraph note that "Post-Essential Thrombocythemia Myelofibrosis: PERSIST)." should have been "Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1)."Read the original article
format	article
author	Keohane C Radia DH Harrison CN
author_facet	Keohane C Radia DH Harrison CN
author_sort	Keohane C
title	Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
title_short	Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
title_full	Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
title_fullStr	Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
title_full_unstemmed	Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
title_sort	treatment and management of myelofibrosis in the era of jak inhibitors [corrigendum]
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/884bd7fa1e2b4de29133247f5cacc29b
work_keys_str_mv	AT keohanec treatmentandmanagementofmyelofibrosisintheeraofjakinhibitorscorrigendum AT radiadh treatmentandmanagementofmyelofibrosisintheeraofjakinhibitorscorrigendum AT harrisoncn treatmentandmanagementofmyelofibrosisintheeraofjakinhibitorscorrigendum
_version_	1718400662903980032

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Ejemplares similares